Result description
Loop Diagnostics has developed SeptiLoop, an innovative in vitro diagnostic test designed to revolutionize sepsis detection. Unlike traditional diagnostic methods, which focus on identifying pathogens and often take 18–72 hours, SeptiLoop measures the functional immune response of a patient, providing results within just 3 hours.
SeptiLoop is a near patient, blood based functional immune assay that measures TNF alpha production in whole blood after ex vivo stimulation with lipopolysaccharide. It identifies patients with sepsis induced immunosuppression and early bloodstream infection, when clinical scores and conventional biomarkers are still inconclusive.
The test uses a simple workflow with a small volume of lithium heparin whole blood, a stimulation reagent and a lateral flow readout integrated in a compact housing. Results are available in less than 3 hours and can be performed close to the point of care. Health economic analyses in the UK suggest that SeptiLoop can reduce mortality and hospital costs by shortening time to appropriate treatment and avoiding unnecessary admissions and broad spectrum antibiotics.
Addressing target audiences and expressing needs
- Expanding to more markets /finding new customers
- Use of research Infrastructure
- Collaboration
We are targeting hospital decision makers, sepsis experts, emergency and intensive care physicians, as well as investors and funding bodies interested in high impact diagnostics.
Needs include:
• Equity and non dilutive funding to complete post market clinical and health economic studies and to support European and UK market access.
• Commercial partners and distributors with experience launching innovative diagnostic tests for emergency and critical care.
• Clinical collaborators and research organisations willing to run multicentre studies in adult and paediatric sepsis.
- Others/ No specific audience
- Other Actors who can help us fulfil our market potential
- Research and Technology Organisations
R&D, Technology and Innovation aspects
SeptiLoop has completed design and industrialisation, is manufactured under ISO 13485, and has obtained CE IVDR Class C and UKCA certification. Early commercial roll out is in progress in Spain, Italy & UK. Next steps are to scale manufacturing, expand distribution, complete post market clinical and cost effectiveness studies, and obtain reimbursement and health technology assessment decisions.
Yes. SeptiLoop is a single use test kits, which can be integrated into existing hospital workflows. The underlying functional immune assay platform can be extended to other infectious and immune mediated indications, allowing scale across tests, clinical settings and geographies while keeping manufacturing and training needs manageable.
Yes. The test is based on standard lithium heparin blood sampling and a simple, standardised workflow that can be replicated across emergency departments, ICUs and hospital laboratories with minimal additional infrastructure. Training needs are low, and the device is designed for near patient use, which supports replication in many hospital environments, including resource constrained settings.
Yes. Sepsis is a large and growing global burden with high mortality and cost, and current diagnostics are slow and insensitive in the early phase. SeptiLoop addresses this unmet need with strong clinical and economic value, protected by patents and regulatory barriers, and fits into existing hospital purchasing and reimbursement structures. The platform can generate additional revenue from new tests and decision support tools, which supports a long term sustainable business.
- Europe

